Thomas E. Barta, Ph.D.
  • Medicinal Chemistry
  • Organic Chemistry
  • Project Management
  • Due Diligence
  • Competitive Intelligence






Synthetic organic and organometallic chemistry (palladium, boron, silicon, copper, fluorine, phosphorus, directed ortholithiation, olefination, heterocycles, cycloaddition, chiral synthesis, microwave chemistry, protecting groups, carbohydrates). Medicinal chemistry (oncology, inflammation, antiviral, obesity, arthritis, Heat Shock 90, chaperone proteins, tubulin, proteases, kinases, antifolates, NSAID's, COX-2, arachidonic acid cascade, Matrix Metalloproteinases, DMPK, structure-based drug discovery, Autodock). Project management. CRO management. Competitive intelligence. Patents. Technical writing. Problem solving.


  • Helped drive Heat Shock 90 program to Phase I for cancer.
  • Helped move a selective, hydroxamic acid-based Matrix Metalloprotenase inhibitor into Phase I for arthritis.
  • Served on Celebrex (COX-2 ) program.
  • Member, American Chemical Society, including organic and med chem divisions.
  • Member, Inflammation Research Association.
  • Referee, Bioorganic and Medicinal Chemistry Letters; Journal of Organic Chemistry; European Journal of Medicinal Chemistry; and Organic Letters.


Education:

NIH Postdoctoral Fellowship (1987-88):

 Northwestern University;  advisor Professor Anthony G. M. Barrett; Total synthesis of Avermectin

Ph.D. in Organic Chemistry (1987):

University of Rochester;  advisor Professor Robert K. Boeckman; Total synthesis of Tetronolide

B.S. in Chemistry (1981):

Massachusetts Institute of Technology


Work History
  • Independent Consulting, Carrboro, NC (2008-present).
  • BioLeap, Inc. Carrboro, NC (2010-2012), combining in silico fragment- based Drug Discovery and practical synthetic expertise.
  • Serenex, Durham, NC (2003-2008). Proteomics approach to cancer therapeutics.
  • Searle/Monsanto/Pharmacia, Skokie, IL (1988-2003). Inflammation, cancer, HIV targets.
Contact: